Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: J Thorac Cardiovasc Surg. 2022 Jan 23;164(5):1327–1337. doi: 10.1016/j.jtcvs.2022.01.019

FIGURE 5.

FIGURE 5.

Summarization of the main purpose and outcome of the study. Clavien–Dindo classification 1 = deviation from normal postoperative course without the need for intervention; 2 = complication requiring pharmacological intervention including blood transfusion; 3 = complication requiring invasive intervention; 4 = complication requiring intensive care unit care; and 5-death. NEOSTAR, Nivolumab With or Without Ipilimumab in Treating Patients With Previously Untreated Stage I-IIIA Non–Small Cell Lung Cancer; ICON, The Immunogenomic Profiling of NSCLC.